Crispr Therapeutics Ag (CRSP)
$199.88
10.16 (4.84%)
CRSP Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
9.36B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
4.00M
Day's Range
199.01 - 220.20
52-Week Range
32.30 - 220.20
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
7 CRISPR Stocks for the Future of Medicine
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.
CRSP Stock: Why CRISPR Therapeutics Shares Are Climbing Today
CRSP stock is rallying today as CRISPR Therapeutics and its gene-editing peers move into the spotlight. Here's what you should know.
Volatility May Continue, But CRISPR Stock Remains a Buy
Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock.
Crispr Stock Is Volatile, but Worth the Wait as a Buy-and-Hold Biotech Play
This Swiss biotechnology company works on the cutting edge of gene editing and Crispr stock is a play on future treatments.
Crispr Therapeutics News: CRSP Stock Slides 12% on Trial Death
Crispr Therapeutics (CRSP) news for Wednesday includes a patient's death during a recent drug trial dropping CRSP stock down.
CRISPR Therapeutics Stock Is a Strong Buy on the Dip
CRSP stock has pulled back 13% in the last two sessions — on no news. The dip allows investors into a strong long-term story at a lower price.
How to Find the Top Stocks in the Hottest Sectors
Here's how a sector fund can help you find top stocks in sizzling sectors. They’re a great place to start, especially when you want to gain exposure to a specific hypergrowth trend.
Is CRISPR Therapeutics Worth It Without Drugs?
We're still very early in the development of gene editing, and CRISPR Therapeutics is one of the first out of the block. But it's not hte final word.
The Future Could Be Soon for Crispr Therapeutics
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
3 Reasons to Go Long Crispr Therapeutics
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
CRISPR Therapeutics Is a Worthwhile Investment in Transformative Science
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
7 Beautiful Biotech Stocks to Buy Here
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
